Barinthus Biotherapeutics plc. (BRNS): Nasdaq/NYSE listing notice — Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR

Barinthus Biotherapeutics plc.

On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
Company has 180 calendar days, until June 29, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
If not compliant by deadline, a second 180-day period may be available if certain conditions are met; company evaluating options including a reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Barinthus Biotherapeutics plc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 30, 2025, Barinthus Biotherapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s American Depositary Shares (the “ADS”), each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-26-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.